Literature DB >> 23404140

Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer.

Fuqiang Yin1, Xia Liu, Danrong Li, Qi Wang, Wei Zhang, Li Li.   

Abstract

Chemokine (C-C motif) ligand 21 (CCL21) and SPARC-like protein 1 (SPARCL1/MAST9/hevin/SC-1) are associated with various biological behavior in the development of cancers. Although the expression of CCL21 and SPARCL1 is downregulated in many solid tumors, their roles in ovarian cancer and their associations with drug resistance have rarely been studied. We performed a comprehensive bioinformatic analysis consisting of motif analysis, literature co-occurrence, gene/protein-gene/protein interaction network, protein-small molecule interaction network, and microRNAs enrichments which revealed that CCL21 and SPARCL1 directly or indirectly interact with a number of genes, proteins, small molecules and pathways associated with drug resistance in ovarian and other cancers. These results suggested that CCL21 and SPARCL1 may contribute to drug resistance in ovarian cancer. This study provided important information for further investigation of drug resistance-related functions of CCL21 and SPARCL1 in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404140     DOI: 10.3892/ijo.2013.1819

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy.

Authors:  Lishuang Qi; Yang Li; Yuan Qin; Gengen Shi; Tianhao Li; Jiasheng Wang; Libin Chen; Yunyan Gu; Wenyuan Zhao; Zheng Guo
Journal:  Br J Cancer       Date:  2016-11-17       Impact factor: 7.640

2.  Associations of tumor suppressor SPARCL1 with cancer progression and prognosis.

Authors:  Ting Li; Xia Liu; Antai Yang; Wenjie Fu; Fuqiang Yin; Xiaoyun Zeng
Journal:  Oncol Lett       Date:  2017-07-08       Impact factor: 2.967

3.  Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression.

Authors:  Alexandra R Harris; Matthew J Perez; Jennifer M Munson
Journal:  BMC Cancer       Date:  2018-07-06       Impact factor: 4.430

Review 4.  Role of CC Chemokines Subfamily in the Platinum Drugs Resistance Promotion in Cancer.

Authors:  Maria E Reyes; Marjorie de La Fuente; Marcela Hermoso; Carmen G Ili; Priscilla Brebi
Journal:  Front Immunol       Date:  2020-05-15       Impact factor: 7.561

Review 5.  Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment.

Authors:  Concetta Altamura; Maria Raffaella Greco; Maria Rosaria Carratù; Rosa Angela Cardone; Jean-François Desaphy
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

Review 6.  CXC and CC chemokines as angiogenic modulators in nonhaematological tumors.

Authors:  Matteo Santoni; Sergio Bracarda; Massimo Nabissi; Francesco Massari; Alessandro Conti; Emilio Bria; Giampaolo Tortora; Giorgio Santoni; Stefano Cascinu
Journal:  Biomed Res Int       Date:  2014-05-29       Impact factor: 3.411

7.  Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.

Authors:  Julia Beretov; Valerie C Wasinger; Ewan K A Millar; Peter Schwartz; Peter H Graham; Yong Li
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

8.  Low expression of KCNN3 may affect drug resistance in ovarian cancer.

Authors:  Xia Liu; Luwei Wei; Bingbing Zhao; Xiangxue Cai; Caihua Dong; Fuqiang Yin
Journal:  Mol Med Rep       Date:  2018-05-31       Impact factor: 2.952

9.  SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.

Authors:  Hai-Ping Zhang; Jun Wu; Zhi-Feng Liu; Jing-Wen Gao; Shu-Yu Li
Journal:  Biomed Res Int       Date:  2022-01-24       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.